

Welcome

Myriad Genetics Investor Day
August 11, 2022

Forward-looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company.

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Market growth rates used in this presentation are estimates based on Company and third-party industry research. The reported number of physicians (600K) and patients in Epic's network (250M) were provided by Epic.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad's corporate website at www.myriad.com.

Our vision and opportunity: Better health through genetic insights

Paul J. Diaz, President and CEO





Revealing the power of genetic insights – for everyone

Mission

We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.



Moving from transformation to expansion and growth

Serving a more patient-centric healthcare system

Fast-growing

Personalized

Data-driven



1.3M

Myriad Genetics tests/year

60,000

active ordering physicians

~10%+

YoY

market growth

across

Mental Health,
Women's Health, Oncology

**A trusted
partner with
specialized
expertise**

Collaboration

Inclusion

Simplification

Innovation

Driving value by better serving patients and customers

Listening to patient and customer needs



**Making it easier to
do business with us**

Collaboration

Partnering with
healthcare
innovators

Creating a more
patient-centric
healthcare system



Inclusion

Making genetic testing
more accessible and
affordable

MyRisk™
Hereditary Cancer Test

with RiskScore®
for all ancestries

\$49M

of financial
assistance
provided to

86,000+

eligible patients
in 2021

95%

of payers cover
Myriad
hereditary
cancer testing

New

point of care
financial
accessibility tools
and payment
programs

Simplification and ease of use

Improving the
customer
experience



\$50M

investment in
point-of care
technology and
digital tools

**EMR
integration
600K**

providers will be
able to order
Myriad
test for **250M**
patients in Epic
network*

Customer-centric, tech-enabled tools to reduce complexity and cost

Innovation

Elevating our products, investing in our labs

Innovative new product pipeline and state-of-the-art labs



\$80M

investment in state-of-the-art Labs of the Future

\$25M+

annual incremental investment in research and development

Up next

Executing to win

Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth



Mark Verratti
Chief Commercial Officer

Engaging our team

Driving service and operational excellence

Enhancing core lab capabilities

Supporting growth, productivity, and innovation | Lab of the Future



Nicole Lambert
Chief Operating Officer

Tech-enabled commercial capabilities

Improving the customer experience and driving growth



Kevin Haas, Ph.D.
Chief Technology Officer

What's next

Innovating and elevating our product pipeline



Dale Muzzey, Ph.D.
Chief Scientific Officer

Delivering value

Long-term growth and profitability



Bryan Riggsbee
Chief Financial Officer

Executing to win

Expanding commercial sales and marketing capabilities
to increase access to genetic testing and drive growth


Mark Verratti, Chief Commercial Officer



Scaling our enterprise commercial platform is a strategic imperative

Competitive intelligence and market planning
Brand management and marketing
Sales operations and performance management
Product/channel management
Tech-enabled customer experience

High potential,
innovative products



Our commercial transformation journey

2021
Reset
the base



2022
Implement new commercial
sales and marketing model



2023
Accelerate
growth





Focus on three major commercial priorities

Priorities	Where we've had success to date	Where we need to further improve
Launch new Myriad Genetics brand and refresh our product messaging	<ul style="list-style-type: none">Narrowed competitive gap vs. competition among healthcare providers and patients on perceptionNamed among Fast Company's most innovative companies in 2021	<ul style="list-style-type: none">Increase engagement with Genetic Counselor community
Deploy new commercial sales and marketing capabilities: Data-driven segmentation, digital lead generation, Inside Sales	<ul style="list-style-type: none">Successfully deployed new commercial sales and marketing capabilities in Mental Health with above expected results	<ul style="list-style-type: none">Deploy new commercial sales and marketing model in Women's Health and OncologyAdapt our go-to-market model to large health systems by building enterprise-wide relationships
Extend our value beyond product quality to lead on the experience and accessibility	<ul style="list-style-type: none">Solved for price transparency and patient affordabilityPartnered with EPIC	<ul style="list-style-type: none">Refocus messaging on improvements in healthcare provider experience and accessibilityRoll out unified ordering portal and ongoing improvements to Myriad Complete™Investing \$50M+ in technology to continue to close gap on customer experience

Our transformation is driving change in perception

Efforts to improve customer experience resulted in 10-point improvement in familiarity of Myriad Genetics brand


Investments in collaboration and relationship-building with healthcare providers resulted in an increase in likelihood to recommend, and improved overall perception



75%

vs. 70% in 2020


of HCPs would consider recommending Myriad's tests to their patients



75%

vs. 68% in 2020

of HCPs said Myriad was a good partner to them in supporting their patients



of HCPs have a better opinion of Myriad compared to a prior study (vs. 66% no change and 2% with a worse opinion)

New commercial model proven out by GeneSight results

Mental Health

GeneSight®

Mental Health Medication Test

~5m patients diagnosed with depression, anxiety and ADHD who failed their first medication

<15% being tested with Mental Health PGx today

100K high potential providers



+35%

expected YoY
(2021 to 2022)
revenue growth¹



+3K

New providers
added every quarter
in 2022



1.6M

Website visitors
per year²



4x

ROI on advertising
media spend³




1. 55% revenue growth and 44% volume growth in H1 22 vs. H1 21

2. Annualized based on 809K visitors from January to June 2022

3. ROI calculated based on orders generated from leads multiplied by average ASP vs. advertising media YTD spend

More effective and scalable commercial sales and marketing model



Data shown represent the past 12 months of activity

Large under-penetrated market opportunities remain in our core business to unlock growth potential across our products

Hereditary Cancer

MyRisk™

Hereditary Cancer Test

RiskScore®

~29M unaffected women meeting NCCN guidelines

24% eligible patients being tested today

50K+ potential providers

Prenatal

Foresight®

Carrier Screen

Prequel®

Prenatal Screen

~3.55M addressable pregnancies

~30% eligible patients being tested with NIPS and ~20% eligible patients with carrier screening

38K+ potential providers

Tumor Profiling

Precise™ Tumor

Molecular Profile Test

MyChoice® CDx

Myriad HRD Companion Diagnostic Test

Prolaris®

Prostate Cancer Prognostic Test

~775K newly diagnosed cancer patients

<40% being tested today

26K+ potential providers

New Myriad Commercial Sales and Marketing Model

Expand our reach to a much larger provider base

Diversify our mode of interaction with providers to meet their preference

Educate patients and providers on an ongoing basis


Create easier paths to access for patients and providers who want to use our tests

Relentless focus on patient and clinician experience

Myriad's Customer Experience (CX) program confirms the need for an outstanding **patient and clinician experience**

For Myriad's customers, **experience is paramount** over other key drivers like innovation and data transparency

What drives clinicians' likelihood to recommend Myriad?




Myriad Complete™

Translating experience into commercial growth

Hereditary Cancer improvements

- **Larger** populations identification
- **Simplified** ordering process for providers
- **Cost transparency** with patients
- **Seamless** integration into clinical workflows
- **Drive decisions** with key insights



We are dedicated to bringing this commercialization strategy to our customers at scale

Our path to 12%+ organic revenue growth target by 2024

Convey Myriad's competitive differentiation and our commitment to being a **reliable genetic testing partner** to patients and providers

Extend **commercial sales and marketing model from Mental Health to Women's Health and Oncology** to reach a broader set of physicians and raise awareness with patients who should be tested

Continue to **make it easier to partner with us**: ease of ordering, EHR integration, data sharing for clinical care and scientific research, testing at home

Successfully launch **FirstGene, Precise Liquid and Precise MRD** for Pharma use in 2023



Engaging our team

Driving service and operational excellence
Key Performance Indicators (KPIs)

Nicole Lambert, Chief Operating Officer



Enterprise Key Performance Indicators (KPIs)




- **Objective: Holistic view of the drivers of our success**
 - Teams engaged in our success and motivated to deliver the highest quality and customer experience fuels our growth and productivity
 - A fact-driven approach to surfacing trouble spots and root causes fosters a healthy learning-focused culture
- **Current focus**
 - Enabling commercial leaders with Business Unit and product-level data and a consistent cadence for review
 - Standardizing and automating delivery of the data



People measures and trending

Employee turnover


▼ 25% Y/Y



% of our team who voluntarily left Myriad over the last 12 months

Employee engagement


▲ 20% Y/Y



% of our team who are satisfied and committed to the organization and its goals

Diversity & inclusiveness

56% % of total HC as of Q2 '22



% of our executive leadership who represent various ethnicities, gender and orientation



Quality measures and trending

Total turnaround time

▼ **15% faster Y/Y**



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Average number of days required to produce a report after the sample is received

Customer NPS

72 %

“Net Promoter Score” is the number of customers who are advocates of Myriad

Audit findings

Holding steady



Q4 '21 Q1 '22 Q2 '22

The number of non-conformance findings surfaced by audits each quarter that drive continuous improvement efforts



Growth trends

Total active customers trends

▲ 30% since Q2'20



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Number of current active healthcare providers ordering tests

Demand volume trends

▲ 12% Y/Y



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Total number of distinct patient samples received in each quarter

Average Selling Price

Holding steady



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Average Selling Price is the total Revenue divided by the total number of units sold



Productivity measures and trends

COGS per Test

▼ **8%** since Q2'20



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Average COGS \$'s per test quarterly
(total Cost of Goods dollars divided by the number
of total units sold to inflation adjusted)

Adjusted OpEx as a % of revenue

▼ **10%** since Q2'20



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Adjusted Operating Expenses divided by
total Revenue each quarter

Sales productivity

▲ **65%** since Q2'20



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Total average revenue generated by each
sales maker (revenue / sales headcount)



Financials

Total revenue

\$179 million




Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Revenue generated each quarter from current orders + collections from tests run in previous quarters

Adjusted Operating income

\$4.5 million



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Adjusted Operating Income is Myriad's profit after all enterprise expenses are accounted for

Adjusted Gross margin

72%



Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22

Adjusted Gross margin is total revenue less the Cost of Goods Sold (COGS)

Enhancing core lab capabilities

Supporting growth, productivity, and innovation
Lab of the Future



Lab of the Future – Vision

Energized and inspired workforce focused on innovation and knowledge-based activities

Automated production for accuracy, efficiency, and minimal turnaround time variation

Differentiated products developed at speed

Environmentally responsible footprint



Salt Lake City

South
San Francisco

Mason, OH

Cologne,
Germany


Lab of the Future – Strategy



- Build best-in-class facilities, streamline real estate portfolio and lab costs
- Establish sites for development and future M&A
- Design scalable, environmentally responsible spaces








- Reignite our high-performance culture
- Leverage investment in modern facilities to enhance recruiting and retention
- Create career advancement opportunities and enhance workforce capabilities
- Increase integration between Myriad sites




- Unify software and hardware platforms
- Improve efficiency, standardize operations, faster assay development
- Enable high-throughput Next Generation Sequencing operations in new, expanded Salt Lake City facility

Multifaceted program to fuel growth and productivity

Broad scope to comprehend all elements of our lab operations

WORKSTREAMS	<div>ASSAY ENHANCEMENT</div> <div>  </div> <div>New features for current products</div>	<div>INNOVATION</div> <div>  </div> <div>New differentiated product offerings</div>	<div>REAL ESTATE</div> <div>  </div> <div>Modernize & streamline real estate portfolio</div>	<div>SCALE FOR GROWTH</div> <div>  </div> <div>Geographically align high-throughput assays</div>	<div>AUTOMATION</div> <div>  </div> <div>Automated backbone for lab operations</div>
FOCUS AREAS	<div>Advanced sequencing</div> <ul style="list-style-type: none"> • MyChoice • Foresight • Prequel • Advance whole exome across the portfolio 	<div>Develop new products</div> <ul style="list-style-type: none"> • FirstGene • Liquid biopsy • MRD 	<div>Build world-class labs</div> <ul style="list-style-type: none"> • New Bay Area facility • New Salt Lake City facility • Mason renovation 	<div>Move existing labs</div> <ul style="list-style-type: none"> • Foresight/Prequel to Salt Lake City • Move existing Salt Lake labs to modern facilities 	<div>Reduce tech debt</div> <ul style="list-style-type: none"> • MyRisk • Foresight • Future NGS assays
KPI IMPACT	<ul style="list-style-type: none"> ✓ Lower COGS ✓ Improve ordering customer experience 	<ul style="list-style-type: none"> ✓ Increased volume ✓ Increased revenue ✓ Year-over-year growth 	<ul style="list-style-type: none"> ✓ Turnover, retention ✓ Improved (audit) quality ✓ Real estate footprint and rent reduction 	<ul style="list-style-type: none"> ✓ Lower (staffing) OpEx ✓ Lower (real estate) OpEx ✓ Lower COGS 	<ul style="list-style-type: none"> ✓ Lower COGS ✓ Improved (audit) quality ✓ Faster turn around times

Execution plan supported by significant investment and top talent



\$80M*
investment in modern labs to deliver

\$12M
annual savings, plus rent reductions starting in 2025

* >85% of investment is estimated to be Capitalizable expense


Tech-enabled commercial capabilities

Improving the customer experience and driving growth

Kevin Haas, Ph.D., Chief Technology Officer




Technology transformation at Myriad




Comprehensive enterprise platform for enabling precision medicine

Myriad Complete™
simplifies and
streamlines the
genetic screening
and testing process




Consistent delivery of tech-enabled commercial capabilities for GeneSight




Sales execution fueling strong recovery and **~40%** CAGR since 2020


Unified provider and patient portals planned to launch for Women's Health 2H 2022



Integrate MyGeneHistory to identify those patients who meet criteria



Electronically order Foresight, Prequel and MyRisk
Manage all results




Expand patient portal to receive MyRisk results and schedule counseling

New opportunity for cross-selling Prenatal and Hereditary Cancer products

70% of Women's Health accounts don't yet order both

Myriad Virtual Care: A new, telehealth hereditary cancer risk action program in partnership with our providers who would like to offer MyRisk testing




Launches Q3 and will be offered to 100 OBGYN offices and breast image centers

EMR accelerating growth with 900+ systems to date across 42 different vendors


Volume growth

Over the past 16 months, we have seen ~25% same store sales uplift post-integration across product lines



Acceleration

Forecasted to go-live with 650 clinic integrations in 2022
35% YoY increase



Natively integrate into clinical EMR workflows for ordering and results

Planned:

Myriad
genetics

+

Epic

Partnership

Turnkey integration: of Myriad portfolio leveraging Epic's 400 participant CareEverywhere network

Full throttle acceleration: For Q4 pilot go-live and early 2023 general availability

Facilitate deeper genomic data sharing:

- Structured genomic results
- Full test Variant Call Files (VCFs)

Opportunity

Volume growth: Projected 25% volume lift per existing client for the >25% of current Myriad accounts using Epic today

Market access: Target large health systems overwhelmingly on Epic

50% of practices with 25 or more physicians are on Epic




Health data intelligence powering next generation in precision medicine innovation

Health. Illuminated.

^
Data

Myriad is working to be a partner in the health data ecosystem

Create a stronger value proposition that allows our customers to more effectively leverage genetic data to improve patient care by pairing our products with real world evidence



Harness large dataset to facilitate effective research collaboration

Run retrospective analysis across millions of anonymized samples joined with phenotypes

- MyChoice + Precise + treatment
- MyRisk + indications + family history
- GeneSight + pharmacy + patient survey
- Prequel + Foresight + FirstGene + outcomes

Powering advances in breast cancer risk assessment

MyRisk[™]
Hereditary Cancer Test

with RiskScore[®]
for all ancestries

Genetic results **7 million**

Variant curations **2 million**

Low-coverage whole genomes **850K**

Sample biobank **450K**

Provide access to data and contribute to the healthcare community by integrating into open source standards and extensible platforms



Tools, Workflows
& Visualization



Clinical Outcomes
EMR data extraction



Treatment, Cohorts,
Longitudinal Study



Privacy, Use &
Access Controls



Improve
treatment
decisions and
patient care

Share and
optimize protocol
best practices


Identify and **recruit**
trial candidates
faster & easier

Support research
and innovation of
new products

Reinforce clinical
utility of genetic
insights

Enable population
health economics
studies

Precise Oncology Solutions Treatment Registry: Driving adoption through health data intelligence




Goal:
100k de-identified,
patients in 3 years



Germline, Tumor
and Liquid
genetic data



Treatments &
Outcomes capture
from EMR




Apollo Multi-omics
collaboration
platform

DNAnexus®

35+
researchers already
enrolled in registry

25%
are new to
Myriad



What's next

Innovating and elevating our product pipeline

Dale Muzzey, Ph.D., Chief Scientific Officer



Outline

GeneSight

Additional clinical support for efficacy

Precise Tumor and Liquid

Robust tumor profiling & therapy selection

Precise MRD

Superior minimal residual disease monitoring

FirstGene

4-in-1 prenatal screening



PRIME Care Randomized Clinical Trial (RCT)



Why GeneSight matters

8.4%

of U.S. adults suffer from major depressive disorder¹

63%

of US adults with major depressive disorder do not achieve remission with first-line drug²

~4

weeks to switch from a drug that is not working to another drug³

GeneSight can help patients find a medication most compatible with their genetics

¹ 2020 National Survey on Drug Use and Health (NSDUH, NIH)

² Rush et al., STAR*D report, 2006, American Journal of Psychiatry

³ Ogle et al., 2012, Journal of Pharmacy Practice


History of evidence supporting GeneSight efficacy

Study	Design	N	
Hamm	Prospective, open-label, controlled	44	Hall-Flavin et al. 2012
La Crosse	Prospective, open-label, controlled	165	Hall-Flavin et al. 2013
Pine Rest	Prospective, blinded, RCT	49	Winner et al. 2013
GUIDED	Prospective, blinded, RCT	1,167	Greden et al. 2019
GDI GUIDED post hoc analysis	Post-Hoc, green-bin meds included	787	Thase et al. 2019
HAM-D6 GUIDED post hoc analysis	Post-Hoc, HAM-D6 outcomes	1,298	Dunlop et al. 2019
65+ GUIDED post hoc analysis	Post-Hoc, Age 65+ cohort	184	Forester et al. 2020
Med Blood Levels GUIDED post hoc analysis	Post-Hoc, validation algorithm	191 124	Shelton et al. 2020 Parikh et al. 2022
CPGx vs Single Gene GUIDED post hoc analysis	Post-Hoc, Blood level (B) & outcomes (O)	O: 1.022 B: 1.034	Rothschild et al. 2021
Meta-Analysis	Hamm, La Crosse, Pine Reset, GUIDED	1,556	Brown et al. 2020
IMPACT	Prospective, open-label, controlled	1,871	Hebert et al. 2018 Tanner et al. 2018


PRIME Care randomized clinical trial investigated efficacy of GeneSight

- 1,944 U.S. Veterans, age 18-80 inclusive
- Suffering from major depressive disorder
- At least one prior treatment episode or intent to switch treatment

Study design:



PHQ-9 overview:



PRIME Care RCT: Both co-primary outcomes were met

Co-primary outcome #1:

Does access to GeneSight testing lower the proportion of antidepressant prescriptions with predicted gene-drug interactions compared to TAU?

YES

GeneSight® Psychotropic

COMBINATORIAL PHARMACOGENOMIC TEST

genesight®

Patient, Sample

DOB: 7/22/1984

Order Number: 9904

Report Date: 6/22/2016

Clinician: Sample Clinician

Reference: 1456CIP

?

Questions? Call 855.891.9415 or email medinfo@assurexhealth.com

ANTIDEPRESSANTS

USE AS DIRECTED

desvenlafaxine (Pristiq®)

levomilnacipran (Fetzima®)

vilazodone (Viibryd®)

MODERATE GENE-DRUG INTERACTION

trazodone (Desyrel®)1

venlafaxine (Effexor®)1

selegiline (Emsam®)2

fluoxetine (Prozac®)1,4

citalopram (Celexa®)3,4

escitalopram (Lexapro®)3,4

sertraline (Zoloft®)3,4

SIGNIFICANT GENE-DRUG INTERACTION

bupropion (Wellbutrin®)1,6

mirtazapine (Remeron®)1,6

amitriptyline (Elavil®)3,8

clomipramine (Anafranil®)1,6,8

desipramine (Norpramin®)1,6,8

doxepin (Sinequan®)1,6,8

duloxetine (Cymbalta®)1,6,8

imipramine (Tofranil®)1,6,8


nortriptyline (Pamelor®)1,6,8

vortioxetine (Trintellix®)1,6,8

fluvoxamine (Luvox®)1,4,6,8

paroxetine (Paxil®)1,4,6,8

TAU = treatment as usual




PRIME Care RCT: Both co-primary outcomes were met

Co-primary outcome #2:

Over a 24-week timeframe, does access to GeneSight testing significantly improve the likelihood of achieving depression remission compared to TAU?

YES




TAU = treatment as usual

The GeneSight arm had a **28%** greater likelihood of achieving remission (p=0.02)

The road ahead for GeneSight R&D

- Continued clinical validity and clinical utility assessment in patients with major depressive disorder
- Verifying efficacy for treatment of postpartum depression:



Precise Tumor and Liquid Biopsy



Challenging to pick the right therapy for a given cancer



Genomic profiling of the tumor can pinpoint which therapy is best



Patients need targeted therapy-selection guidance via either tissue or liquid biopsy


Precise™ Tumor

Molecular Profile Test



Precise™ Liquid


Molecular Profile Test



*Launch planned
for 2023*

- Offered in collaboration with Illumina and Intermountain Healthcare
- Both solid and liquid assays test >500 genes, including DNA and RNA analysis
- Precise Liquid can serve as stand-alone product for certain indications and reflex for cases where solid tumor sample is insufficient or low-quality

Building a complete suite of oncology services



Building a complete suite of oncology services

MyChoice® CDx

Myriad HRD Companion Diagnostic Test

Precise™ Tumor

Molecular Profile Test

← Precise Liquid in 2023

BRACAnalysis CDx®

Germline Companion Diagnostic Test

EndoPredict®

Breast Cancer Prognostic Test

MyRisk™
Hereditary Cancer Test

MyRisk™
Hereditary Cancer Test
RiskScore®



Precise Minimal Residual Disease (MRD)



MRD monitoring helps address two fundamental questions



Is my cancer treatment working?

If not:

Shift to a new approach




Has my cancer recurred?


If so:

Option to resume treatment early

MRD detects DNA ejected from dying tumor cells: More DNA = More tumor



In-house MRD built upon Myriad's existing core competencies




Myriad MRD expected to more deeply interrogate the tumor than other MRD offerings

Somatic
variant
identification

Competitor


Exome



Number of sites
interrogated in
plasma sample


Competitor

16 sites




More sites ► Higher sensitivity ► Earlier detection of recurrence


Assessing analytical performance on Stage II breast cancer sample



Excellent analytical performance on Stage II breast cancer sample



Looking at more somatic sites enables superior detection at low tumor fraction



Pursuing a range of MRD initiatives

- Amassing samples to power analytical validation study
- Leveraging pharma partnerships from MyChoice CDx
- Collaborating with Intermountain Healthcare on a prospective study for MRD
- Planning a large, multi-site, prospective clinical utility study that will launch in 2023
- Preparing laboratory automation for research use only (RUO) launch in early 2023




FirstGene



An OBGYN may see more than 30 women in a day




Each patient needs multifaceted care



10-week visit checklist

- ✓ Breast exam
- ✓ Pelvic exam
- ✓ Pap smear
- ✓ Vaccination check for MMR
- ✓ Rh type testing
- ✓ Emotional status check
- ✓ Noninvasive prenatal screening
- ✓ Carrier screening

OBGYNs tell us that they sometimes don't have time to offer genetic testing




10-week visit checklist

- ✓ Breast exam
- ✓ Pelvic exam
- ✓ Pap smear
- ✓ Vaccination check for MMR
- ✓ Rh type testing
- ✓ Emotional status check
- ✓ Noninvasive prenatal screening
- ~~Carrier screening~~

Carrier screening requires two tests and education about the complexity of underlying genetics

Is my child going to be affected with a severe genetic condition?



Screen mother for recessive carrier status

If mother is a carrier of certain condition(s), screen the father to determine carrier status for those conditions

If both are carriers, then the fetus has a 25% chance of being affected

Each patient needs multifaceted care





“


*If you make
me talk
about
genetics for
30 more
seconds
per patient,
I hate you.”*


—OBGYN at MWH
ad board

50% of women don't currently get carrier screening




 Not offered carrier screening

 Screened positive; Reproductive partner unscreened

 Screened positive; partner also screened

 Screened negative

>50% of women also don't currently undergo NIPS



⊘ Didn't undergo NIPS

The integrated solution for basic prenatal screening

FirstGene



The integrated solution for basic prenatal screening

FirstGeneticTest



The integrated solution for basic prenatal screening

FirstGeneticTest


FirstGene™

4-in-1 Prenatal Screen




FirstGene™

4-in-1 Prenatal Screen



NIPS for common
aneuploidies



Carrier screening for
common conditions



Fetal recessive status
(affected, carrier, normal)




Feto-maternal blood
compatibility


Single blood
draw on one
person




No need
to screen!



FirstGene is not simply a combination of Foresight and Prequel



NIPS for common aneuploidies



Carrier screening for common conditions



Fetal recessive status (affected, carrier, normal)



Feto-maternal blood compatibility

Gamechanger

- Eliminates need for sequential testing workflow
- Fewer pregnancies need diagnostic follow-up
- Those undergoing diagnostic testing much more likely to be positive

What is tested on FirstGene?

NIPS for common
aneuploidies



Carrier screening for
common conditions



Fetal recessive status
(affected, carrier, normal)




Feto-maternal blood
compatibility

- **Trisomies 13/18/21** (*guideline-recommended*)
- (Opt-in) Sex-chromosome analysis
- (Opt-in) 22q11.2 microdeletion syndrome


- **Cystic Fibrosis** (*guideline-recommended*)
- **Spinal Muscular Atrophy** (*guideline-recommended*)
- (Opt-in) Beta-chain hemoglobinopathies (e.g., Sickle Cell Disease)
- (Opt-in) Alpha thalassemia
- (Opt-in) 10 additional common genes selected to maximize equity in care
- (Opt-in) Fragile X (maternal carrier status only)

- (Opt-in) Maternal and fetal RHD copy-number analysis

Multiple levels of fetal-fraction amplification in FirstGene



Take the AMPLIFY technology from Prequel...



... and port to FirstGene for superior fetal fraction

FirstGene estimated to have

3X

fewer samples with inconclusive fetal recessive results due to low fetal fraction*

FirstGene clinical study underway

- Will power FirstGene analytical and clinical validity publications
- Enrolling 500 patients for development and validation – enrollment underway
- For each pregnancy, we will collect:
 - Screening sample (plasma)
 - Diagnostic sample (CVS or amniocentesis)



Austin Maternal-Fetal Medicine

Advantages relative to alternative approaches

FirstGene™

4-in-1 Prenatal Screen

3X

the number of
genes¹

2X

faster
turnaround
time for fetal
affected
status²

3X

fewer samples
with
inconclusive
fetal recessive
results due to
low fetal
fraction³

3X

lower COGS⁴

¹ Expected panel size of FirstGene compared to UnityScreen panel

² FirstGene will perform fetal recessive testing in a single assay, rather than two sequential assays


³ Based on comparison between FirstGene internal data and Westin et al., 2022, American Journal of Hematology

⁴ Based on internal analysis of running FirstGene versus separately running carrier screening, aneuploidy NIPS, and single-gene NIPS



FirstGene is a truly integrated offering


Competitor's offering



- All four assays run separately but offered in an integrated report
- Longer TAT
- Higher COGS


FirstGene™

4-in-1 Prenatal Screen



- All four assays run in single, integrated assay
- Shorter TAT
- Lower COGS

Myriad prenatal portfolio can serve all needs




 **FirstGene™**
4-in-1 Prenatal Screen

 **Prequel®**
Prenatal Screen

 **Foresight®**
Carrier Screen

FirstGene expected
to be available 2023

Roadmap



Delivering value

Long-term growth and profitability

Bryan Riggsbee, Chief Financial Officer



Foundation for organic growth



9-12%

estimated organic
revenue growth
'22-'24

\$638
2021
Revenue¹

\$665
LTM 6/30
Revenue

~\$670 -700
2022
Revenue
Guidance

1

MyRisk stabilization

- Recent 15 gene expansion for RiskScore for all ancestries
- Streamlined ordering and EMR integration
- New commercial sales and marketing model

2

+4-5%

Mental Health

- GeneSight® momentum

3

+3-4%

Women's Health

- FirstGene™ -- Combined Prequel and Foresight product launch
- Expanded medical association guidelines

4

+2-3%

Oncology

- Precise™ oncology solution launch
- MyChoice™ CDx expansion
- Prolaris® momentum
- Precise™ Liquid launch in 2023

5

Accelerating
growth rate in
'24+

Upside

- New oncology solutions including liquid biopsy and MRD
- Women's Health product and channel expansion
- Companion diagnostics expansion of indications and pharma partnerships
- M&A / strategic partnerships

Highly efficient and scalable revenue cycle operations

1. Reflects "base" revenue in millions, and excludes revenue from divested businesses and COVID-19 testing

Mental Health: Significant GeneSight growth

 **4-5%** estimated contribution to '22-'24 organic revenue growth

Recent performance: GeneSight showing strong momentum in 2022

Revenue
(\$ in Millions)

55%
Growth

\$40

\$62

1H 2021

1H 2022

Next two years: Key growth drivers

GeneSight®
Mental Health Medication Test


Double-digit growth

Continued channel expansion along with increased physician adoption


Additional published studies, including the PRIME study, to drive increased awareness and increased commercial coverage

Ongoing macro tailwinds supporting increased focus on mental health and pharmacogenomics


Women's Health: FirstGene launch to accelerate growth

 **3-4%** estimated contribution to '22-'24 organic revenue growth


Recent performance: Prenatal products driving growth



Next two years: Key growth drivers




Oncology: Strength across portfolio

 **2-3%** estimated contribution to '22-'24 organic revenue growth


Recent performance: Strong tumor profiling growth

Tumor Profiling Revenue
(\$ in Millions)



Next two years: Key growth drivers

Low-to-mid single digit growth



Project Phoenix: Discipline and governance

Performance management
and accountability

Sustained staff
engagement

Operational
visibility



A scalable approach

A robust organizational
alignment model


Standard processes
and procedures

Consumer-centric
workflows

Project Phoenix: Customer experience

Approach: Unifying operations to remove customer friction

Impact



Improved patient experience via improved operational outcomes and accelerated balance resolution



Improved communication among internal and external customers



Improved employee experience via consistent expectations, increasing confidence and pride

Project Phoenix: Financial impact



Increase in average cash collected per order



Reduction in prior authorization and billing backlog



15% improvement in prior authorization success



15-20% increase in billing and prior authorization employee productivity

Significant progress achieved since 2020

Goals from May 2021 Investor Day

100-150 bps

in gross margin
expansion over three years

\$55-\$60M

annualized
run-rate OpEx
savings by FY 2022

Return to

profitability

and positive free
cash flow by Q4 2021

Progress

2020A	Adj. Gross Margin		2022 Guidance
	2021A	1H 2022A	
68%	72%	72%	~70-72%

2020A	Adj. OpEx as % of Sales		2022 Guidance
	2021A	1H 2022A	
82%	70%	71%	~70-71%


2020A	Adj. EPS		2022 Guidance
	2021A	1H 2022A	
(\$0.66)	\$0.02	\$0.01	(\$0.10)-\$0.00

Commentary

- Gross margin expansion driven by optimization initiatives and lab efficiencies
- Reduction in run-rate OpEx as demonstrated by lower expense margin, driven by commercial reorganization, overhead savings from divestitures, and focused expense management
- Positive operating income via diligent expense management
- Approaching positive FCF

Strong and healthy balance sheet

Key Balance Sheet items as of June 30, 2022:



Revenue reconciliation

In millions	Fiscal Year 2021	Last Twelve Months Ended 6/30/2022 ²
Total Revenue	\$690.6	\$672.4
Revenue from Divested businesses & COVID-19 Testing ¹	\$(52.3)	\$(7.5)
Base Revenue	\$638.3	\$664.9

1. Represents total revenue earned prior the divestitures of the Myriad myPath, LLC laboratory and Myriad RBM, Inc. in Q2 2021 and the Myriad Autoimmune business in Q3 2021. Additionally, prior to Q3 2021, the Company performed a limited amount of COVID-19 testing as a result of the pandemic.

2. Represents the last twelve months of revenue for the period ended June 30, 2022.

Closing remarks


Paul J. Diaz, President and CEO



Investment considerations: Myriad strengths and strategic advantages

Leader in genetic testing and precision medicine

- Transformation and growth strategy on track
- Broad and growing commercial capabilities with 60K healthcare providers ordering Myriad products across Women's Health, Oncology and Mental Health
- Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities
- Trusted, differentiated healthcare partner with specialized expertise



Q&A



Appendix

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com

Key takeaways

- Early success in our transformation journey and the reset of our base of operations:
 - Reorganized and energized our team/culture/business processes to better serve our customers and support growth
 - Reduced complexity, lowered cost, and redesigned our commercial model to improve our operating and financial results
 - Launched several initiatives to improve our competitive position, elevate our products to their full potential, and accelerate growth
- Creating new avenues for long-term growth and profitability through new enterprise capabilities, R&D, technological innovations, M&A, and new partnerships

